Date: 2017-05-12
Type of information: Nomination
Compound: chief executive officer
Company: Molecular Partners (Switzerland)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 12, 2017, Molecular Partners announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, co-founder of the company, as Chief Executive Officer and to nominate him to become a member of the Board of Directors.
When Christian Zahnd resigned as CEO of Molecular Partners in November 2016, the Board of Directors appointed Patrick Amstutz as acting CEO, and engaged in a process to find the best suitable internal or external candidate. The Board of Directors is pleased to have concluded that Patrick Amstutz is best qualified to become the next CEO of the company.
Financial terms:
Latest news:
Is general: Yes
